TY - JOUR
T1 - Incidence, predictive factors and oncological outcomes of incidental prostate cancer after endoscopic enucleation of the prostate
T2 - a systematic review and meta-analysis
AU - Cheng, Bryan Kwun Chung
AU - Castellani, Daniele
AU - Chan, Ivan Sik Hei
AU - Baker, Abu
AU - Gauhar, Vineet
AU - Wroclawski, Marcelo Langer
AU - Santamaria, Hegel Trujillo
AU - Tanidir, Yiloren
AU - Enikeev, Dmitry
AU - Chan, Vinson Wai Shun
AU - Ng, Chi Fai
AU - Herrmann, Thomas
AU - Teoh, Jeremy Yuen Chun
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/1
Y1 - 2022/1
N2 - Introduction: This systematic review aims at reporting the incidence, predictive factors, and the oncological outcomes of incidental prostate cancer (IPCa) in men who underwent endoscopic enucleation of prostate (EEP). Methods: A literature search was performed using the following Medical Subject Heading (MeSH) terms and keywords: “Prostatic Neoplasms”, “Prostate Cancer”, “Transurethral Resection of Prostate”, “Prostate resection”, “Prostate enucleation”. Meta-analysis was performed if there were two or more studies reporting the same outcome under the same definition. In case of insufficient data, results were presented in a narrative manner. Results: Sixty-one studies were included in qualitative synthesis and 55 were included in meta-analysis. The pooled IPCa rate was 0.08 (95% CI 0.073–0.088). Increasing age, higher preoperative serum prostate-specific antigen (PSA) level, higher preoperative PSA density (PSAD), smaller prostate volume, higher postoperative PSA velocity and lower enucleated prostate weight, were reported to have significant correlation with IPCa. In BPH patients, the mean pre-operative and post-operative PSA levels were 5.58 ± 1.48 ng/dL and 1.06 ± 0.27 ng/dL, respectively. In patients with IPCa, the mean pre-operative and post-operative PSA levels were 7.72 ± 2.90 ng/dL and 2.77 ± 1.66 ng/dL, respectively. The mean percentage PSA reduction was 82.0% ± 1.8% for BPH patients and 68.2% ± 12.1% for IPCa patients. IPCa was most commonly managed by active surveillance (68.7%). Conclusions: The pooled incidence of IPCa after EEP was 8%. An absolute post-operative PSA level of < 2.0 and a percentage PSA reduction of > 70% should be expected in BPH patients after EEP.
AB - Introduction: This systematic review aims at reporting the incidence, predictive factors, and the oncological outcomes of incidental prostate cancer (IPCa) in men who underwent endoscopic enucleation of prostate (EEP). Methods: A literature search was performed using the following Medical Subject Heading (MeSH) terms and keywords: “Prostatic Neoplasms”, “Prostate Cancer”, “Transurethral Resection of Prostate”, “Prostate resection”, “Prostate enucleation”. Meta-analysis was performed if there were two or more studies reporting the same outcome under the same definition. In case of insufficient data, results were presented in a narrative manner. Results: Sixty-one studies were included in qualitative synthesis and 55 were included in meta-analysis. The pooled IPCa rate was 0.08 (95% CI 0.073–0.088). Increasing age, higher preoperative serum prostate-specific antigen (PSA) level, higher preoperative PSA density (PSAD), smaller prostate volume, higher postoperative PSA velocity and lower enucleated prostate weight, were reported to have significant correlation with IPCa. In BPH patients, the mean pre-operative and post-operative PSA levels were 5.58 ± 1.48 ng/dL and 1.06 ± 0.27 ng/dL, respectively. In patients with IPCa, the mean pre-operative and post-operative PSA levels were 7.72 ± 2.90 ng/dL and 2.77 ± 1.66 ng/dL, respectively. The mean percentage PSA reduction was 82.0% ± 1.8% for BPH patients and 68.2% ± 12.1% for IPCa patients. IPCa was most commonly managed by active surveillance (68.7%). Conclusions: The pooled incidence of IPCa after EEP was 8%. An absolute post-operative PSA level of < 2.0 and a percentage PSA reduction of > 70% should be expected in BPH patients after EEP.
UR - http://www.scopus.com/inward/record.url?scp=85108111217&partnerID=8YFLogxK
U2 - 10.1007/s00345-021-03756-9
DO - 10.1007/s00345-021-03756-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 34142230
AN - SCOPUS:85108111217
SN - 0724-4983
VL - 40
SP - 87
EP - 101
JO - World Journal of Urology
JF - World Journal of Urology
IS - 1
ER -